...mos. In the D arm, 1 CR pt remains alive and disease free at 27+ mos; the second pt died of progressive disease at 20 mo...
...mos.,None of the schedules of 209-2M + HD IL-2 produced better activity than expected with IL-2 alone. Arm 3 with greate...
...mos 1-6, 8, 10, 12. OS and TTP were primary and secondary endpoints respectively.,133 pts were evaluable. 12% of pts wer...
...mos). Four tumor cores per sample (i.e.: 4 replica) were included in TMA blocks. We evaluated the expression of ER, PgR,...
...mos (range 0.1-9.1+ mos) and median OS 18.3 mos (range 1.1-18.3+ mos). Data will be available on all 41 patients in May,...
...mos and 53 mos, respectively. Specifically, four patients (0.25%) developed axillary recurrence, 2 in the SLND group (0....
...mos. and energy and fatigue at 12 mos. (r=0.71, p=0.002); Hg at 6 mos. and role limitations due to physical problems at ...
...mos (range 5-12). Kaplan-Meier estimate of 8 mos OS was 81% and the PFS 42,8%. Toxicity (NCI criteria) in the 26 pts eva...
...mos, p<0.0001] & 4-mo PFS (10% vs 22%, p=0.04). OCN > 0.89 ng/mL had better 4-mo PFS (12% vs 20%, p=0.01). PINP and PIII...
...mos (1-80 mos).,This was an open phase III trial comparing 5 years of TAM vs 2-3 years of TAM followed by 3-2 years of A...
联系地址
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话： 0531-88819269
版权所有 © 2025.Genelibs 济南弘晖生物技术有限公司 鲁ICP备20007159号-2
